Compare Stocks: LFCR, DRUG, CRMD, and CTNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$8.13 -0.6%	$8.09	$6.13 ▼ $13.48	$637.59M	1.5	1.42 million shs	928,235 shs
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$599.68M	0.75	506,840 shs	388,829 shs
DRUG Bright Minds Biosciences	$65.06 -2.8%	$74.33	$41.48 ▼ $123.75	$651.18M	-5.36	108,296 shs	43,211 shs
LFCR Lifecore Biomedical	$4.09 -5.1%	$4.59	$3.63 ▼ $8.98	$163.15M	1.08	119,580 shs	264,784 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-0.61%	-5.57%	+7.97%	-9.26%	-37.61%
CTNM Contineum Therapeutics	-5.02%	-12.18%	+4.49%	+27.66%	+20.93%
DRUG Bright Minds Biosciences	-2.76%	-8.52%	-19.47%	+5.67%	+54.28%
LFCR Lifecore Biomedical	-5.10%	-13.71%	-12.23%	-27.61%	-43.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$8.13 -0.6%	$8.09	$6.13 ▼ $13.48	$637.59M	1.5	1.42 million shs	928,235 shs
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$599.68M	0.75	506,840 shs	388,829 shs
DRUG Bright Minds Biosciences	$65.06 -2.8%	$74.33	$41.48 ▼ $123.75	$651.18M	-5.36	108,296 shs	43,211 shs
LFCR Lifecore Biomedical	$4.09 -5.1%	$4.59	$3.63 ▼ $8.98	$163.15M	1.08	119,580 shs	264,784 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-0.61%	-5.57%	+7.97%	-9.26%	-37.61%
CTNM Contineum Therapeutics	-5.02%	-12.18%	+4.49%	+27.66%	+20.93%
DRUG Bright Minds Biosciences	-2.76%	-8.52%	-19.47%	+5.67%	+54.28%
LFCR Lifecore Biomedical	-5.10%	-13.71%	-12.23%	-27.61%	-43.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.75	Moderate Buy	$15.00	84.50% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	33.75% Upside
DRUG Bright Minds Biosciences	3.00	Buy	$143.83	121.08% Upside
LFCR Lifecore Biomedical	2.00	Hold	$6.50	58.92% Upside

Current Analyst Ratings Breakdown

Latest LFCR, DRUG, CRMD, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Perform
8/20/2026	DRUG Bright Minds Biosciences	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00
8/17/2026	DRUG Bright Minds Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$147.00
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/4/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/29/2026	LFCR Lifecore Biomedical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/21/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$311.71M	2.03	$2.03 per share	4.00	$5.14 per share	1.58
CTNM Contineum Therapeutics	$50M	11.39	N/A	N/A	$6.99 per share	2.17
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
LFCR Lifecore Biomedical	$128.87M	1.20	N/A	N/A	$0.42 per share	9.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	$163.05M	$2.14	3.80	58.07	N/A	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	N/A
LFCR Lifecore Biomedical	N/A	-$1.07	N/A	N/A	N/A	-29.93%	N/A	-16.16%	10/2/2026 (Estimated)

Latest LFCR, DRUG, CRMD, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/5/2026	Q2 2026	LFCR Lifecore Biomedical	-$0.19	-$0.19	N/A	-$0.19	$34.18 million	$34.17 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	0.31	2.56	2.36
CTNM Contineum Therapeutics	N/A	37.17	37.17
DRUG Bright Minds Biosciences	N/A	122.00	122.00
LFCR Lifecore Biomedical	N/A	3.87	2.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
CTNM Contineum Therapeutics	N/A
DRUG Bright Minds Biosciences	40.52%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.50%
CTNM Contineum Therapeutics	7.90%
DRUG Bright Minds Biosciences	42.66%
LFCR Lifecore Biomedical	32.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	77.94 million	75.22 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
DRUG Bright Minds Biosciences	N/A	9.73 million	5.58 million	Not Optionable
LFCR Lifecore Biomedical	690	37.85 million	25.48 million	Optionable

LFCR, DRUG, CRMD, and CTNM Headlines

Recent News About These Companies

BlackRock Inc. Acquires New Stake in Lifecore Biomedical, Inc. $LFCR

September 5, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Lifecore Biomedical (LFCR)

September 4, 2026 | theglobeandmail.com

Lifecore Biomedical to Participate at CPHI Global Conference

September 3, 2026 | globenewswire.com

Lifecore Biomedical Adds New Commercial Program, Expands 2028 Revenue Pipeline; Stock Up

September 2, 2026 | rttnews.com

Lifecore Biomedical Signs New Commercial Transfer Agreement for Marketed Injectable Product

September 2, 2026 | quiverquant.comQ

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

September 2, 2026 | globenewswire.com

Lifecore Biomedical Earnings Call Balances Growth and Strain

August 21, 2026 | tipranks.com

424,500 Shares in Lifecore Biomedical, Inc. $LFCR Acquired by DCF Advisers LLC

August 20, 2026 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

August 6, 2026 | theglobeandmail.com

Lifecore reaffirms 2026 guidance, outlines fill/finish demand doubling in 2027 and +200% growth in 2028

August 5, 2026 | seekingalpha.com

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Lifecore Biomedical: Q2 Earnings Snapshot

August 5, 2026 | leadertelegram.comL

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

August 5, 2026 | markets.businessinsider.com

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

August 5, 2026 | globenewswire.com

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

July 29, 2026 | globenewswire.com

Lifecore Biomedical Signs Three New Customer Agreements

July 28, 2026 | finance.yahoo.com

Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs

July 28, 2026 | quiverquant.comQ

Lifecore Biomedical Signs Three New Customer Agreements

July 28, 2026 | globenewswire.com

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2026 | globenewswire.com

Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market

July 15, 2026 | insidermonkey.com

Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LFCR, DRUG, CRMD, and CTNM Company Descriptions

CorMedix NASDAQ:CRMD

$8.13 -0.05 (-0.61%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$8.15 +0.02 (+0.25%)

As of 09/9/2026 07:30 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Contineum Therapeutics NASDAQ:CTNM

$15.14 -0.80 (-5.02%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$15.14 +0.00 (+0.03%)

As of 09/9/2026 07:30 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Bright Minds Biosciences NASDAQ:DRUG

$65.06 -1.85 (-2.76%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$65.24 +0.17 (+0.27%)

As of 09/9/2026 07:30 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Lifecore Biomedical NASDAQ:LFCR

$4.09 -0.22 (-5.10%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$4.08 -0.01 (-0.24%)

As of 09/9/2026 07:30 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFCR, DRUG, CRMD, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFCR, DRUG, CRMD, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFCR, DRUG, CRMD, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LFCR, DRUG, CRMD, and CTNM Company Descriptions

CorMedix NASDAQ:CRMD

Contineum Therapeutics NASDAQ:CTNM

Bright Minds Biosciences NASDAQ:DRUG

Lifecore Biomedical NASDAQ:LFCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LFCR, DRUG, CRMD, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LFCR, DRUG, CRMD, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LFCR, DRUG, CRMD, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LFCR, DRUG, CRMD, and CTNM Company Descriptions

CorMedix NASDAQ:CRMD

Contineum Therapeutics NASDAQ:CTNM

Bright Minds Biosciences NASDAQ:DRUG

Lifecore Biomedical NASDAQ:LFCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools